Bifinorm (Lyophilisate) Instructions for Use
Marketing Authorization Holder
St. Petersburg Research Institute of Vaccines and Sera of the FMBA, FSUE (Russia)
ATC Code
A07FA (Antidiarrheal microorganisms)
Active Substance
Bifidobacterium bifidum (Grouping name)
Dosage Form
| Bifinorm | Lyophilizate for the preparation of suspension for oral and topical administration 5 doses: fl. 10 pcs. |
Dosage Form, Packaging, and Composition
| Lyophilizate for the preparation of suspension for oral and topical administration | 1 dose | 1 fl. |
| Bifidobacterium bifidum | 10 million CFU | 5 doses |
5 doses – bottles (10) – carton packs.
Clinical-Pharmacological Group
Drug regulating the balance of intestinal microflora (probiotic)
Pharmacotherapeutic Group
MIBP-eubiotic
Pharmacological Action
Live bifidobacteria possess high antagonistic activity against a wide range of pathogenic and opportunistic microorganisms of the intestine (including staphylococci, Proteus, enteropathogenic Escherichia coli, Shigella, some yeast-like fungi).
They restore the balance of intestinal and vaginal microflora, normalize the digestive and protective functions of the intestine, activate metabolic processes, and increase the body’s nonspecific resistance.
Indications
Treatment and prevention of dysbiosis of various etiologies in children and adults.
Prolonged intestinal dysfunctions of unspecified etiology; acute intestinal infections (as part of the complex treatment of acute dysentery, salmonellosis, escherichiosis, viral diarrheas), prolonged intestinal dysfunctions of staphylococcal etiology, as well as treatment of convalescents after acute intestinal infections with persistent intestinal dysfunction; as part of the complex treatment of children (including newborns, premature infants) with pneumonia, sepsis and other purulent-infectious diseases, for the prevention or relief of their intestinal function disorders and prevention of the development of ulcerative-necrotizing enterocolitis; children with a burdened premorbid state: born prematurely or with signs of prematurity, receiving antibiotics in the early neonatal period; children whose mothers suffered from severe toxicosis, extragenital diseases, had a long waterless period or other pathology; children of mothers who have lactostasis, cracked nipples and are resuming breastfeeding after recovery from mastitis; weakened children with anemia, hypotrophy, rickets, diathesis and other manifestations of allergy; in whooping cough disease, especially in the presence of any intestinal function disorders; with early transfer of infants to artificial feeding; acute and chronic inflammatory diseases of the large and small intestine (colitis, enterocolitis) in older children and adults, occurring against the background of microflora disorders with a deficiency or absence of bifidoflora; intestinal dysfunctions as a result of intestinal dysbiosis arising from long-term antibacterial, hormonal, radiation and other therapy, during stressful situations and staying in extreme conditions, as well as for the purpose of preventing dysbiosis.
For the prevention of mastitis for local treatment of the mammary glands of nursing mothers at risk (in women with inverted flat nipple, reduced erection, presence of cracks) in a complex epidemiological situation in maternity hospitals.
In diseases of the female genital area: in case of violation of the purity of vaginal secretion to III-IV degree in pregnant women at risk; in bacterial colpitis caused by staphylococcus and Escherichia coli (in monoflora or in associations), as well as in senile colpitis of hormonal nature.
ICD codes
| ICD-10 code | Indication |
| A02 | Other salmonella infections |
| A03 | Shigellosis |
| A04.8 | Other specified bacterial intestinal infections |
| A05.0 | Staphylococcal food poisoning |
| A08.4 | Viral intestinal infection, unspecified |
| A09.0 | Other and unspecified gastroenteritis and colitis of infectious origin (infectious diarrhea NOS) |
| K52.9 | Noninfective gastroenteritis and colitis, unspecified |
| K63.8 | Other specified diseases of intestine |
| N76 | Other inflammatory diseases of vagina and vulva |
| N77.1 | Vaginitis, vulvitis and vulvovaginitis in infectious and parasitic diseases classified elsewhere |
| N89.8 | Other noninflammatory disorders of vagina |
| N95.2 | Postmenopausal atrophic vaginitis |
| O91 | Infections of the breast associated with childbirth |
| O92.0 | Retracted nipple |
| O92.1 | Cracked nipple associated with childbirth |
| P23 | Congenital pneumonia |
| P36 | Bacterial sepsis of newborn |
| P92.9 | Feeding problem of newborn, unspecified |
| Y40 | Systemically acting antibiotics |
| Y42 | Hormones and their synthetic substitutes and antagonists, not elsewhere classified |
| Y84.2 | Radiological procedure and radiotherapy |
| Z29.8 | Other specified prophylactic measures |
| Z51.4 | Preparatory procedures for subsequent treatment or examination, not elsewhere classified |
| ICD-11 code | Indication |
| 1A02 | Intestinal infections due to Shigella |
| 1A09.Z | Salmonella infection, unspecified |
| 1A0Z | Bacterial intestinal infections, unspecified |
| 1A10 | Staphylococcal food poisoning |
| 1A2Y | Other specified viral intestinal infections |
| 1A2Z | Viral intestinal infections, unspecified |
| 1A40.Z | Infectious gastroenteritis or colitis, unspecified |
| 1F23.10 | Candidiasis of vulva and vagina |
| 1F65 | Enterobiasis |
| 1H0Z | Unspecified infection |
| DA90.0 | Syndromic diarrhea |
| DA92.1 | Pneumatosis intestinalis of the small intestine |
| DA98.Z | Polyps of small intestine, unspecified |
| DB31.1 | Pneumatosis of the colon |
| DB36.Z | Certain infections of the colon, unspecified |
| DE2Z | Diseases of the digestive system, unspecified |
| GA00 | Vulvitis |
| GA02.Z | Unspecified vaginitis |
| GA0Z | Inflammatory diseases of female genital tract, unspecified |
| GA30.2 | Postmenopausal atrophic vaginitis |
| GC42.1 | Painful intercourse |
| JB45.Z | Infections of the breast associated with childbirth, unspecified |
| JB46.0 | Retraction of nipple associated with childbirth |
| JB46.1 | Cracked nipple associated with childbirth |
| KA60 | Fetal or neonatal sepsis |
| KB24 | Congenital pneumonia |
| KD32.Z | Feeding problems of newborn, unspecified |
| MF3A | Vaginal discharge |
| PK81.C | Radiotherapy causing injury or harm in the course of therapeutic use |
| PL00 | Drugs, medicaments or biological substances causing injury or harm in therapeutic use |
| QB9A | Preparatory procedures for subsequent treatment |
| QC05.Z | Prophylactic measures, unspecified |
| 1A0Y | Other specified bacterial intestinal infections |
| XN9W5 | Enterobacter species |
| 1A94.0 | Genital or urogenital tract infection caused by Herpes simplex virus |
| GA41 | Ulcerative or erosive diseases of vulva |
| GA1Z | Unspecified noninflammatory disorders of female genital tract |
| XA1LK7 | Vagina |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
For oral and topical administration.
Prepare the suspension immediately before use. Open the vial and add chilled boiled water. Use approximately 5 ml of water per one dose. Shake until a homogeneous suspension is obtained.
For oral administration, take the prepared suspension 20-30 minutes before a meal.
For intestinal dysbiosis in adults, administer 5 doses orally 2-3 times per day. The treatment course is typically 14-21 days.
For children, the dose is 5 doses orally 2-3 times per day. The duration of treatment is determined individually.
For infants, administer 2.5 doses orally 2 times per day. For premature and low birth weight infants, use 1.25 doses orally 2 times per day.
For acute intestinal infections, use the drug for 5-7 days.
For topical use in gynecological practice, apply 5-10 doses, diluted in 15-20 ml of water, for vaginal irrigation or tampons once daily for 8-10 days.
For mastitis prevention, treat the nipple area and areola with a swab moistened with the prepared suspension from 2.5 doses for 5-10 minutes before feeding. Continue for 5 days.
Do not dissolve the lyophilisate in water with a temperature exceeding 40°C. Do not store the prepared suspension.
Adverse Reactions
Possible allergic reactions, nausea.
Contraindications
Individual intolerance.
Use in Pregnancy and Lactation
Can be used during pregnancy and breastfeeding according to indications in appropriate dosage forms.
Use in Hepatic Impairment
The drug is approved for use in hepatic impairment.
Use in Renal Impairment
The drug is approved for use in renal impairment.
Pediatric Use
In children (including premature infants) it can be used from the first days of life in dosage forms intended for this category of patients according to age.
Geriatric Use
Approved for use in elderly patients.
Special Precautions
Simultaneous use of oral forms with antibiotics is not recommended, as well as dissolving the drug in hot water (above 40°C) and storing it in dissolved form.
The use of suppositories can be combined with the simultaneous administration of antibacterial, antiviral, and immunostimulating drugs.
Drug Interactions
When taken simultaneously with chemo- and antibacterial drugs, a decrease in therapeutic efficacy is possible.
The action of drugs containing Bifidobacterium bifidum is enhanced by vitamins (especially B vitamins).
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer